COMy 2021 | Who should undergo MRD monitoring in myeloma?
Bruno Paiva
• 7 May 2021
The clinical value of measurable residual disease (MRD) in multiple myeloma has become apparent in recent years, with growing data to support its use as a prognostic marker, clinical trial endpoint, and aid for clinical decision making. Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the optimal use of MRD monitoring in myeloma. MRD is a useful measure of depth of response and thus, Dr Paiva believes all patients achieving a negative result by immunofixation should undergo MRD assessment. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
